Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Table 3 Discontinuations (several reasons could be given in parallel

^aOther reasons: in the etanercept cohort, patient’s/parent’s wish (n = 6); no further visits by the patient (n = 2), treatment with approved biologic available (n = 2), no restart after an adverse event although it disappeared (n = 2), reason not reported (n = 3); in patients on anakinra, a patient was admitted to a clinical trial (n = 1), reason not reported (n = 2); in patients on tocilizumab, reason not reported (n = 3)

ISSN: 1478-6362